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Viewpoint
Leishmaniases’ Burden of Disease: Ways Forward for
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In this month’s issue of PLoS Neglected
Tropical Diseases, Bern et al. [1] review the
disease burden of the leishmaniases. In
their article, the authors review the clinical
pathology and eco-epidemiology of the
disease as well as provide us with current
data on the morbidity, mortality, and
socioeconomic impact of the leishmaniases
throughout their endemic range. They
conclude that ‘‘current methods of assessing
disease burden fail to take into account the
clinical and epidemiological diversity’’ of
the leishmaniases and the ‘‘intense medical,
social and economic impact’’ that they
might have in highly affected foci.
Bern et al. [1] rightly argue that
estimates of the burden of the leishmani-
ases, both in terms of morbidity and
mortality, or in terms of disability adjusted
life years (DALYs), are outdated, and/or it
is unclear how currently used numbers are
derived. Up-to-date figures would assist in
garnering funding and political support for
the prevention and control of this neglect-
ed tropical disease. Clearly, such revised
figures could be obtained in a number of
ways, including by (i) discussing whether
used estimates are actually accurate and/
or up-to-date (referring to the commonly
used, below-mentioned figures, whether
right or wrong); (ii) reviewing whether the
methodology to estimate past or current
numbers is adequate; or (iii) describing a
way forward to collect data allowing for
more robust disease burden estimates. In
their review, Bern et al. [1] primarily focus
on the former, reviewing reports from
several countries showing an increase in
leishmaniases case numbers. Based on
these reports, the authors conclude that
the disease burden of the leishmaniases is
inaccurate and out-of-date, and the reader
is left thinking that it must be higher than
currently acknowledged. Additionally, it is
highlighted that the approach and formula
to estimate the burden of leishmaniases, in
terms of DALYs, is flawed: namely, that
the values of the used visceral and
cutaneous leishmaniasis disability weight
and other input parameters are erroneous.
Unfortunately, it is unclear from Bern et
al.’s arguments [1] what the value of
DALY input parameters should be, and
as such, their criticism is similar to the
criticisms levelled with regards to the
burden of disease of every infectious
disease of public health importance [2,3].
Thus, how does one go about in
quantifying the burden of the leishmania-
ses more accurately? The aim of this
viewpoint is to elaborate on points (ii)
and (iii) above, which with the data
reviewed by Bern et al. [1] will provide a
platform from where a more accurate
estimate of the leishmaniases’ burden of
disease can be obtained.
Distribution, Prevalence,
Incidence, and Burden of
Disease: Current Status or
‘‘When Numbers Are Cited
Repeatedly, They Invariably
Become Hard Fact’’
The leishmaniases are believed to be
endemic in 88 countries [4]. Broadly
speaking, the leishmaniases can be divided
into two larger groups of diseases: visceral
leishmaniasis (VL) and cutaneous leish-
maniasis (CL) [5,6]. VL is a chronic,
systemic disease characterized by fever,
(hepato)splenomegaly, lymphadenopathy,
pancytopenia, weight loss, weakness, and,
if left untreated, death. CL is generally
non-fatal and is characterized by a com-
paratively benign disease that is limited to
the skin and that may spontaneously cure.
However, as the review by Bern et al.
points out [1], because CL represents most
of the leishmaniases cases worldwide and
because it may progress to severe disease
(e.g., leishmaniasis recidivans, mucosal
leishmaniasis) resulting in significant social
stigma of the affected population, CL’s
impact on morbidity and quality of life can
be considerable.
Whereas 90% of VL cases reportedly
occur in Bangladesh, Brazil, Ethiopia,
India, Nepal, and Sudan, 90% of CL cases
are believed to occur in Afghanistan,
Algeria, Brazil, Pakistan, Peru, Saudi Ara-
bia, and Syria. Over the years, there has
been significant discrepancy with regards to
the data describing the burden of the
leishmaniases [7–13]. At present, according
to the World Health Organization (WHO)
figures, every year it is estimated that 1.5–2
million leishmaniases cases and up to
51,000 deaths due to the leishmaniases
occur [4,12,13]. A total of 350 million
people are at risk of infection and disease,
and infection prevalence is estimated at 12
million cases. The leishmaniases are, in
terms of DALYs, the third most important
vector-borne disease, with an estimated 2.4
million DALYs [13]. These figures have
been and are used repeatedly by researchers
(including the current author), program
managers, and policy makers, even though
the source of these data is alreadymore than
a decade old [9].
Putting the Spotlight on
Disease Burden Input
Parameters
Burden of disease is commonly ex-
pressed as prevalence or incidence of
disease morbidity and mortality, quality
adjusted life years (QALYs) or DALYs (see
Box 1 for a glossary of terms). DALYs
were established in 1992 during the first
Global Burden of Diseases (GBD) study to
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enable health professionals and policy
makers to create a scalable measure of
disease impact for all health states, which
could be extrapolated to country, regional,
or global levels to aid in priority setting
enabling more (cost)effective implementa-
tion of health programs [14].
To answer the question on how to
estimate the leishmaniases’ burden of
disease more accurately, one has to look
at the disease burden input parameters,
irrespective of whether it is estimated in
prevalence or incidence of leishmaniases
morbidity and mortality, or DALYs.
Moreover, such analysis should be done,
whether or not the formula to calculate
DALYs is deemed valid or complete [2,3].
Assuming that some of the generic input
parameters (i.e., standard life expectation,
age weight, future discount) [2,3,14] to
estimate the leishmaniases’ burden of
disease in terms of DALYs are beyond
discussion, one is left with four disease-
specific input parameters that warrant
special attention: age at death, prevalence
of disease, duration of disease, and dis-
ability weight.
Age at death and mortality. Com-
pared to other major vector-borne diseases
and in the absence of major epidemics (e.g.,
as the one in Sudan during 1980s that is
presumed to have caused up to 100,000
deaths among 280,000 people) [15],
mortality due to the leishmaniases has so
far been assumed to be limited to VL, with
all 51,000 fatalities reported due to VL [13];
fatalities due to CL are very rare and usually
due to co-infections or treatment complica-
tions [6].
Age at death varies according to the
endemic setting, with younger age groups
affected in established VL transmission
settings and older age groups affected in
new VL foci. Thus, the GBD study
assumed that 10% and 49% of deaths
occurred in age groups ,5 and ,15 years
of age, respectively [14]. Unfortunately,
no comprehensive data sets exist that
could assess whether this distribution is
valid, but it is known that VL incidence is
substantially greater in younger age groups
if malnutrition is present [16].
A recent study has shown that fatalities
due to VL have probably been drastically
underestimated. Thus, reviewing clinical
records at clinics in Southern Sudan, a
study by Collin et al. [17] estimated that
91% of deaths from VL were not reported
and, thus, undetected. Also, it has become
evident in the past decades that both CL
and particularly VL have become an
opportunistic infection of HIV/AIDS
patients [5,6], often contributing to their
demise, with VL increasing the risk of
mortality by more than 3-fold. [18]
Prevalence of disease. Although the
leishmaniases are endemic in 88 countries,
they may not be a notifiable disease in
many of them. Also, because of the
comparatively benign nature of CL,
inaccessibility of health services in rural,
endemic areas, and the common non-
availability of treatment, severe under-
reporting of the leishmaniases is observed
(e.g., by a factor of 1:40 for CL in
Guatemala) [19].
Moreover, the leishmaniases, particu-
larly VL, have similar clinical symptoms as
other, more prevalent diseases in endemic
areas, including malaria and schistosomi-
asis—to what extent VL is misdiagnosed
as, for example, these two diseases is not
known. Co-infection with other diseases
are possible, as recently shown in Uganda,
where malaria was diagnosed in 6.4% of
VL cases attending clinical facilities for VL
treatment [20].
It is difficult to ascertain whether the
estimate of 1.5–2 million annual cases of CL
and VL is correct. As mentioned above and
highlighted in the review by Bern et al. [1],
passive case detection lacks sensitivity and
large-scale leishmaniases prevalence surveys
are scarce. Of note, however, is that
according to the GBD study, for the
leishmaniases 66 data sources were included
to yield used estimates [14], compared to
282, 117, 89, and 55 for dengue, malaria,
lymphatic filariasis, and schistomiasis, re-
spectively. As is highlighted, most of that
leishmaniases data appears to be based on
an ‘‘approximate estimate from current
WHO database’’, because ‘‘original extrac-
tion from surveillance data source is not
available’’ [14].
Duration of disease. Again, it is
unclear what input parameter values were
used for duration of disease in current
leishmaniases disease burden estimates.
For VL, duration of disease can be up to
2.5 months until diagnosis and treatment
[17], depending on infecting parasite
species, genetic host factors, and immuno-
supression (e.g., due to malnutrition or
HIV/AIDS). If not treated, VL patients
rarely spontaneously cure, with 95% case
fatality rates reported [5].
For CL, duration of disease is much
more variable, due to the greater number of
species causing disease. [6] Thus, whilst
clinical disease can spontaneously cure
within 2–6 months when due to some
species (e.g., Leishmania major), it can become
chronic if not treated and result in more
severe clinical disease (e.g., leishmaniasis
recidivans andmucosal leishmaniasis) when
due to others (e.g., L. tropica and L.
braziliensis). [6] For most Leishmania spp.
causing CL, duration of disease is greater
than 6 months if not treated.
From current DALY disease burden
estimates, it is unclear whether duration of
disease includes only active disease (i.e.,
lesions) or also CL scars—as mentioned
below, CL scars can have as big of a social
impact as active disease and, hence,
duration of disease should be considered
‘‘life-long’’ from time of appearance of CL
Box 1. Leishmaniases’ Burden of Disease: Definitions
Prevalence. Actual number of cases of disease present in a population at any
particular moment in time.
Incidence. New cases of disease occurring in a specified population in a given
time period.
DALY. Disability adjusted life year. A measure of the gap in healthy years of life
lived by a population as compared with the normal standard. Essentially, DALYs
are a time-based measure that adds together years of life lost due to premature
mortality with the equivalent number of years of life lived with disability or illness.
Disability Weight. Measure of the relative valuations of a health state on an
interval scale. The disability weight quantifies judgements about overall levels of
health associated with different health states, not judgements on the relative lives
lived, persons, or of overall well-being, quality of life, or utility. The weights are
intended to reflect average global valuations; values are between 0 (i.e., state
comparable to ideal health) and 1 (i.e., state comparable to death).
Discounting. Process applied to costs, benefits, and outcomes based on the
concept that there is preference for money in health in the present and relative
future.
Duration of Disease. Average duration of disease (or disability) in years until
remission or death.
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lesions rather than just being limited to the
period of active disease.
Disability weight. The disability
weight for VL and CL is 0.243 and 0.023,
respectively. As Bern et al. point out [1],
where these figures come from and how
these weights were calculated is somewhat
ambiguous, with ‘‘major uncertainties’’ and
‘‘sparse documentation’’ associated with
these figures. Whilst many of the infections
due to Leishmania spp. can be benign, there is
now increasing literature on the social
impact of the leishmaniases, particularly
CL [6]. As in many endemic settings cases
do not have access to prompt diagnosis and
treatment, CL lesions can be of considerable
size and number, and may last for some
considerable time (see above), all of which
may affect treatment response. Even with
successful treatment, a typical CL scar
results, which, depending on location (e.g.,
lesions commonly are on the face due to the
exposure to the sandfly vector), Leishmania
etiology, and type of clinical disease (i.e.,
localized CL versus leishmaniasis recidivans
versus mucosal leishmaniasis), can lead to
significant social stigmatization [21]. It
would be fair to say that compared to this
emotional disability, the leishmaniases’ impact
on physical disability is, overall, moderate.
For VL, impact of infection and disease can
be considerable, with physical disability
affected by the characteristic clinical signs
(i.e., anemia, hepatosplenomegaly). For CL,
physical disability is limited, including at
most minor incapacitation of movement or
manual labor (e.g., if lesions are located on
joints); breathing, swallowing, and talking
(e.g., if extensive mucosal leishmaniasis
affects mucosae or vocal cords); or
urination (e.g., if lesions are located on
sexual organs). For both VL and CL,
physical disability will also occur if patients
undergo the lengthy anti-leishmanial
treatment. Depending on the treatment
approach and route of administration used,
treatment may have considerable (toxic) side
effects (e.g., myalgia, gastroenteritis,
pancreatitis, hepato and cardiac toxicity,
diabetes) [5,6], affecting a patient’s physical
condition. Finally, due to clinical disease,
duration, or cost of treatment, the
leishmaniases may cause considerable
economic disability, with most treatment
approaches exceeding US$200 per patient
treated (note, even though treatment in
many countries is officially free-of-charge,
this often is not the case in practice). Thus, a
recent study from the Indian sub-continent
suggested that, from a household
perspective, each episode of VL was
estimated to be associated with US$217
worth of out-of-pocket expenses and loss of
income, representing 71% of annual
household income [22]. Note, whilst the
GBD study specifically states that it does not
capture diseases’ economic burden (i.e., a
different approach would be required to
estimate economic loss suffered due to the
morbidity or mortality incurred by a disease
or condition) [14], it would be
comparatively easy to include in the
burden calculations direct costs associated
with treatment.
In the absence of clear knowledge of
how the leishmaniases disability weights
were estimated, and taking into account
the leishmaniases’ impact on emotional,
physical, and economic disability, what
should the leishmaniases’ disability weight
be? Without addressing qualitatively and
quantitatively the above issues of emotion-
al, physical, and economic disability first,
this would be hard to determine. Taking
the current disability weight as a bench-
mark, VL is in the range of disabling
leprosy (disability weight: 0.152), malaria
episodes (0.191), dengue hemorrhagic
fever (0.210), onchocerciasis resulting in
low vision (0.260), and trachoma resulting
in low vision (0.278) [14]. CL, on the other
hand, is in the range of malaria-induced
anemia (0.012), hookworm-induced ane-
mia (0.024), onchocerciasis-induced itch-
ing (0.068), and lymphatic filariasis char-
acterised by hydroceles (0.073) [14].
A Way Forward
In light of the above and complementing
the recommendations by Bern et al. [1], the
following should be the minimum that
would be required to obtain an up-to-date
estimate of the leishmaniases’ burden of
disease.
First, a clear understanding should be
obtained as to how current estimates of the
leishmaniases’ burden of disease were
obtained, both in terms of case numbers
as well as DALYs. Moreover, clarification
should be obtained about the nature and
origin of input parameters (e.g., whether
duration of disease for CL includes scars
or only the duration of active CL lesions;
specifying the values of each input param-
eter), and how the disability weight for the
leishmaniases was computed. If necessary,
disease burden estimates should be
amended so as to include the duration of
active disease and scars for CL, as well as
the physical and emotional disability
incurred by both VL and CL; if feasible,
the economic disability incurred by VL
and CL should also be included.
Second, there should be a recommen-
dation, internationally recognized and
endorsed, on uniform leishmaniases case
definitions and clinical and non-clinical
leishmaniases diagnosis algorithms, as well
as standardization of approaches to get
active and passive case detection estimates
in endemic settings. Such harmonization
and standardization would ensure that
collected data is comparable across en-
demic countries as well as enable the
provision of robust data sources for future
burden of disease calculations.
Third, whilst a leishmaniases surveillance
system [1] would be laudable, due to cost
constraints it is probably not feasible in
practice—instead, there should be advocacy
to integrate the leishmaniases with other
disease surveillance programs (e.g., malaria
or Chagas disease), particularly if these have
established sentinel surveillance sites.
Fourth, representative surveys (e.g., sim-
ilar to the Malaria Indicator Surveys
developed under Roll Back Malaria’s
Monitoring and Evaluation Reference
Group [23]) should be carried out at
regular intervals. Such surveys, together
with surveillance data (see above), would
allow for more precise estimates of mor-
bidity and mortality of the leishmaniases
across endemic regions, prevalence of co-
infections, leishmaniases-associated disabil-
ity, and knowledge of the disease diagnosis,
treatment, prevention, and control. A step
in this direction is the developed protocol to
evaluate neglected tropical disease control
programs at the country level [24].
Fifth, sensitivity and specificity analyses
should be carried out using a range of
input parameters to determine more
robust estimates of the disease burden in
terms of DALYs, as well as to show how
input parameters affect current estimates.
Conclusion
As with other diseases where the burden
of disease was re-assessed (e.g., schistoso-
miasis, rabies, diarrhoeal diseases) [25–
27], there is a need to obtain to obtain up-
to-date data on the leishmaniases’ burden
of disease. Only then can a cohesive global
leishmaniases prevention and control strat-
egy be formulated, advocacy be done at
both fundraising and political levels, and
efforts be implemented to significantly
impact disease morbidity and mortality,
and, hence, burden of disease.
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